Government Grants
Business Grants
Home Owner Programs
Federal Programs
About Us
Administrative Supplements to NCI Grant and Cooperative Agreement Awards to Support Collaborations with the PDX Development and Trial Centers Research Network (PDXNet)(Admin Suppl - Clinical Trial Not Allowed)
This administrative supplement funding opportunity announcement is part of the Cancer Moonshot initiative to accelerate cancer research, and was developed in response to a recommendation from the Blue Ribbon Panel of experts charged with advising the National Cancer Advisory Board on the exceptional
scientific opportunities that could be accelerated through this initiative.
As part of the Cancer Moonshot initiative, the National Cancer Institute (NCI) created the Patient-Derived Xenograft (PDX) Development and Trial Centers Research Network (PDXNet), a collaborative network of centers of excellence focused on using patient-derived xenografts and other patient-derived models to accelerate the development of NCI investigational new drug (IND) agents (i.e., those that the NCI is developing in collaboration with pharmaceutical partners) in NCI-sponsored early phase clinical trials.
This FOA supports supplemental funds to current NCI-funded research projects for new interdisciplinary collaborations between non-PDXNet investigators and PDXNet investigators to perform research within the scientific scope(s) of the parent grant and/or cooperative agreement award(s) that will lead to improved pre-clinical evaluations of novel therapeutic concepts using the large-scale PDX model collections of PDXNet, and that could ultimately be tested in NCI-sponsored clinical trials.
scientific opportunities that could be accelerated through this initiative.
As part of the Cancer Moonshot initiative, the National Cancer Institute (NCI) created the Patient-Derived Xenograft (PDX) Development and Trial Centers Research Network (PDXNet), a collaborative network of centers of excellence focused on using patient-derived xenografts and other patient-derived models to accelerate the development of NCI investigational new drug (IND) agents (i.e., those that the NCI is developing in collaboration with pharmaceutical partners) in NCI-sponsored early phase clinical trials.
This FOA supports supplemental funds to current NCI-funded research projects for new interdisciplinary collaborations between non-PDXNet investigators and PDXNet investigators to perform research within the scientific scope(s) of the parent grant and/or cooperative agreement award(s) that will lead to improved pre-clinical evaluations of novel therapeutic concepts using the large-scale PDX model collections of PDXNet, and that could ultimately be tested in NCI-sponsored clinical trials.
Related Programs
Department of Health and Human Services
Department of Health and Human Services
Department of Health and Human Services
Cancer Cause and Prevention Research
Department of Health and Human ServicesCancer Detection and Diagnosis Research
Department of Health and Human ServicesDepartment of Health and Human Services
Department of Health and Human Services
Department of Health and Human Services
Agency: Department of Health and Human Services
Office: National Institutes of Health
Estimated Funding: $500,000
Office: National Institutes of Health
Estimated Funding: $500,000
Who's Eligible
Relevant Nonprofit Program Categories
Obtain Full Opportunity Text:
http://grants.nih.gov/grants/guide/pa-files/PA-18-496.html
Additional Information of Eligibility:
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U. S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.
Non-domestic (non-U.S.) components of U. S. Organizations are not eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Full Opportunity Web Address:
http://grants.nih.gov/grants/guide/pa-files/PA-18-496.html
Contact:
Agency Email Description:
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Agency Email:
Date Posted:
2017-12-15
Application Due Date:
Archive Date:
2018-04-06
Social Entrepreneurship
Spotlight
Calgary Social Enterprise Offers High-Tech Services by People with Autism
Meticulon, a project of Autism Calgary Association in partnership with the federal government and the Sinneave Family Foundation, operates as a social enterprise that renders high-tech services provided by people with autism, leveraging their natural abilities at requiring attention to detail, repetition, and sequencing.
Learn How to Identify and Avoid Grant Scams
